STAT+: Triple hormone receptors, a monthly obesity drug, and a bittersweet ending

STAT PlusNewsletters Triple hormone receptors, a monthly obesity drug, and a bittersweet ending You’re reading the web edition of STAT’s ADA in 30 Seconds Manage alerts for this article Email this article Share this article By Elizabeth CooneyJune 6, 2026 Cardiovascular Disease Reporter Elizabeth Cooney[email protected]Liz covers cardiovascular and metabolic disease, asking why we’re not doing better or even losing ground against the world’s leading killer. Send tips on Signal at LizC.22. You’re reading the web edition of STAT’s ADA in 30 Seconds newsletter, from the American Diabetes Association’s annual conference. Sign up here Welcome back! The American Diabetes Association annual conference is in full swing with news about old and new approaches to treating diabetes.Advertisement Buckle in for a day 2 recap. STAT+ Exclusive Story Already have an account? Log in This article is exclusive to STAT+ subscribers Unlock this article — plus in-depth analysis, newsletters, premium events, and news alerts. Already have an account? Log in Monthly $39 Totals $468 per year $39/month Get Started Totals $468 per year Starter $30 for 3 months, then $399/year $30 for 3 months Get Started Then $399/year Annual $399 Save 15% $399/year Get Started Save 15% 11+ Users Custom Savings start at 25%! Request A Quote Request A Quote Savings start at 25%! 2-10 Users $300 Annually per user $300/year Get Started $300 Annually per user View All Plans To read the rest of this story subscribe to STAT+. Subscribe Log In chronic disease, diabetes, STAT+ Submit a correction requestReprints Elizabeth Cooney Cardiovascular Disease Reporter Liz covers cardiovascular and metabolic disease, asking why we’re not doing better or even losing ground against the world’s leading killer. Send tips on Signal at LizC.22. Newsletter Stay on top of the latest developments coming out of the American Diabetes Association conference. Recommended Newsletters June 5, 2026 STAT Plus: Newer GLP-1s, pushback on research cuts, and a protest Newsletters April 20, 2026 STAT Plus: At AACR, a provocative use of CAR-T, Merck’s new thing and cancer’s geography problem Advertisement Newsletters April 19, 2026 STAT Plus: AACR 2026: More strong data for Revolution Medicines’ KRAS drug Subscriber Picks